- Home
- WGRX vs BTAI Comparison
WGRX vs BTAI Comparison
Compare WGRX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- BTAI
- Stock Information
- Founded
- WGRX 2022
- BTAI 2017
- Country
- WGRX United States
- BTAI United States
- Employees
- WGRX N/A
- BTAI N/A
- Industry
- WGRX Other Pharmaceuticals
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- BTAI Health Care
- Exchange
- WGRX Nasdaq
- BTAI Nasdaq
- Market Cap
- WGRX 43.9M
- BTAI 48.3M
- IPO Year
- WGRX 2025
- BTAI 2018
- Fundamental
- Price
- WGRX $0.66
- BTAI $1.90
- Analyst Decision
- WGRX
- BTAI Buy
- Analyst Count
- WGRX 0
- BTAI 5
- Target Price
- WGRX N/A
- BTAI $32.80
- AVG Volume (30 Days)
- WGRX 41.9M
- BTAI 930.7K
- Earning Date
- WGRX 11-19-2025
- BTAI 11-12-2025
- Dividend Yield
- WGRX N/A
- BTAI N/A
- EPS Growth
- WGRX N/A
- BTAI N/A
- EPS
- WGRX N/A
- BTAI N/A
- Revenue
- WGRX $36,738,599.00
- BTAI $868,000.00
- Revenue This Year
- WGRX N/A
- BTAI N/A
- Revenue Next Year
- WGRX N/A
- BTAI $544.99
- P/E Ratio
- WGRX N/A
- BTAI N/A
- Revenue Growth
- WGRX 82384.51
- BTAI N/A
- 52 Week Low
- WGRX $0.34
- BTAI $1.17
- 52 Week High
- WGRX $7.04
- BTAI $12.16
- Technical
- Relative Strength Index (RSI)
- WGRX 47.00
- BTAI 32.60
- Support Level
- WGRX $0.61
- BTAI $2.14
- Resistance Level
- WGRX $0.82
- BTAI $2.46
- Average True Range (ATR)
- WGRX 0.13
- BTAI 0.14
- MACD
- WGRX 0.03
- BTAI -0.01
- Stochastic Oscillator
- WGRX 27.76
- BTAI 11.43
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.